Pharma DECODED
Latest edition: 14 Jun 2024
Share newsletter
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Spotlight
AbbVie and FutureGen link on inflammatory bowel disease
FutureGen is entitled to receive $1.56bn in milestone payments on meeting specified milestones.
Latest news
UK's new Netflix-style funding model for antibiotics goes live
After a successful trial, the UK NHS has become the first to permanently adopt a subscription payment model for new antibiotics.
Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial
The company plans for an NDA resubmission for reproxalap in the second half of this year.
First patients enrolled on Veris' CCP pilot programme
The programme was launched by Pavmed’s digital health subsidiary Veris Health and the Ohio State University Comprehensive Cancer Center.
WHO publishes new mpox prevention and management framework
The new framework sets out to achieve and sustain the elimination of human-to-human transmission of the disease.
Leo's single-dose autoinjector secures FDA approval for atopic dermatitis
The autoinjector offers adults with moderate-to-severe atopic dermatitis an alternative administration method of Adbry.
Santa Ana Bio secures $168m for inflammatory disease treatments
Since its inception in 2022, Santa Ana has progressed three programmes, with clinical trials expected to begin in 2025.
Suven Pharmaceuticals to gain controlling stake in Sapala Organics
Suven intends to purchase the remaining shares, ultimately owning 100% of Sapala Organics’ share capital.
In our previous edition
Pharma Decoded
FDA approves AstraZeneca's Farxiga for paediatric T2D patients
13 Jun 2024
Pharma Decoded
UK clinical trial sector must address prolonged timelines, say experts
12 Jun 2024
Pharma Decoded
FDA committee unanimously backs Lilly's donanemab bid for Alzheimer's
11 Jun 2024
Still looking?
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Explorer
Access more premium companies when you subscribe to Explorer